<SEC-DOCUMENT>0000313143-14-000033.txt : 20140324
<SEC-HEADER>0000313143-14-000033.hdr.sgml : 20140324
<ACCEPTANCE-DATETIME>20140324113006
ACCESSION NUMBER:		0000313143-14-000033
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140324
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20140324
DATE AS OF CHANGE:		20140324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HAEMONETICS CORP
		CENTRAL INDEX KEY:			0000313143
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				042882273
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0330

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14041
		FILM NUMBER:		14712316

	BUSINESS ADDRESS:	
		STREET 1:		400 WOOD RD
		CITY:			BRAINTREE
		STATE:			MA
		ZIP:			02184
		BUSINESS PHONE:		7818487100

	MAIL ADDRESS:	
		STREET 1:		400 WOOD ROAD
		CITY:			BRAINTREE
		STATE:			MA
		ZIP:			02184
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8kitem801arcpressrelease.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2014 WebFilings LLC. All Rights Reserved -->
		<title>8K Item 8.01 ARC Press Release</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s13fb09c7b48d4a9f8d66d3baf3a2ef43"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:174%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:174%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;8-K</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:174%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:174%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 OR 15(d)&#160;of The Securities Exchange Act of 1934</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported) &#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;March 24, 2014</font></div><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:174%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">HAEMONETICS CORPORATION</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="32%"></td><td width="2%"></td><td width="32%"></td><td width="2%"></td><td width="32%"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Massachusetts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1-14041</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-2882273</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction </font></div><div style="text-align:center;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission </font></div><div style="text-align:center;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer </font></div><div style="text-align:center;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">400 Wood Road, Braintree MA </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">02184</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:174%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">781-848-7100</font><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:174%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or former address, if changed since last report.)</font></div><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4%"></td><td width="96%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s13fb09c7b48d4a9f8d66d3baf3a2ef43"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Item&#160;8.01 Other Events</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:8px;text-align:left;padding-left:5px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On March 24, 2014, Haemonetics Corporation issued a press release with an update on The American Red Cross whole blood tender. The press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by this reference.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s13fb09c7b48d4a9f8d66d3baf3a2ef43"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.8203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="46%"></td><td width="5%"></td><td width="49%"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">HAEMONETICS CORPORATION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 24, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Christopher Lindop</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Christopher Lindop, Vice President</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99103242014arctender.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2014 WebFilings LLC. All Rights Reserved -->
		<title>exhibit99.103242014ARCTender</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sB9450E283A26E307582FF48BFF2C04A0"></a><div><div style="line-height:120%;text-align:center;font-size:20pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.96049896049897%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="a03242014arctenderimage1a01.gif" style="height:62px;width:197px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;color:#c60c30;font-weight:bold;">News Release</font></div></td></tr></table></div></div></div><br><div style="line-height:150%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="9%"></td><td width="38%"></td><td width="53%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FOR RELEASE:</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CONTACT:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March 24, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Gerry Gould, VP-Investor Relations</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Time</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8:00AM Eastern Time&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tel. (781) 356-9402</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">gerry.gould@haemonetics.com </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Alt. (781) 356-9613</font></div></td></tr></table></div></div><div style="line-height:150%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Haemonetics Provides Update on U.S. Whole Blood Supply Tender </font></div><div style="line-height:150%;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">March 24, 2014, Braintree, MA, USA</font><font style="font-family:Arial;font-size:12pt;">&#32;&#8211; Haemonetics Corporation (NYSE: HAE) today announced that it was not selected to supply The American Red Cross with certain whole blood collection components.  The Company was informed that a competitor was chosen to supply these products on an exclusive basis.  &#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Haemonetics provided the following information regarding its whole blood collection kit business with The American Red Cross:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Haemonetics currently supplies 1.8 million in-line whole blood collection kits to the American Red Cross annually; approximately 0.4 million such kits include Haemonetics&#8217; Acrodose platelet pooling product and were not included in the tender. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The remaining 1.4 million kits will begin to be sourced from a competitor commencing early in fiscal 2015.  Annual revenues approximating $25 million in fiscal 2014 will be impacted going forward.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:150%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Company expects that, after appropriate variable cost reductions, earnings per share will be negatively impacted by approximately $0.15 annually upon transition of this business to the competitor. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Brian Concannon, Haemonetics&#8217; President and CEO, commented:  &#8220;While we are disappointed that the American Red Cross has selected a competitor to meet their needs for whole blood collection products, we are not wavering in our resolve to bring differentiating technologies to this marketplace. These include our unique SOLX</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;red cell storage solution, as well as continued automation of the whole blood collection process.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">It is typical of supply agreements of this nature to include options for customers to change vendors should significant technological advances occur during the course of the agreement.  It is Haemonetics&#8217; intention to bring such advances to market.  </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Mr. Concannon continued:  &#8220;The American Red Cross remains an important customer for our apheresis and Acrodose products and we expect to continue to have an important long-term relationship with our nation&#8217;s largest blood collector.  We look forward to demonstrating the value of our innovation and differentiation to all our customers.&#8221;  </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Additionally, the Company noted that approximately 75% of the world&#8217;s annual leukoreduced whole blood collections &#8211; the market Haemonetics participates in &#8211; are outside the U.S.  Ongoing Company initiatives are lowering the cost of its whole blood collection kit, a key enabler to pursuing tenders outside the U.S.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><br><div><div style="line-height:150%;text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">1</font></div><div style="line-height:150%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB9450E283A26E307582FF48BFF2C04A0"></a><div><div style="line-height:120%;text-align:left;"><img src="a03242014arctenderimage1a01.gif" style="height:62px;width:201px;"></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">About Haemonetics</font></div><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:Arial;font-size:4pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;background-color:#ffffff;">Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers.  Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world.  Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.  To learn more about Haemonetics, please visit http://www.haemonetics.com.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Cautionary / Safe Harbor Language</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This release contains forward-looking statements that involve risks and uncertainties, including the effects of </font><font style="font-family:inherit;font-size:12pt;">disruption from our manufacturing transformation activities which may make it more difficult</font><font style="font-family:Arial;font-size:12pt;">&#32;to maintain relationships with employees and timely deliver high quality products, unexpected expenses incurred during our Value Creation and Capture program, technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, demand for whole blood and blood components, product quality, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers&#8217; ordering patterns including single-source tenders, the effect of industry consolidation as seen in the plasma and blood center markets, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive.  </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though inherently uncertain and difficult to predict.  Actual results and experience could differ materially from the forward-looking statements.&#160;Information set forth in this press release is current as of today and the Company undertakes no duty or obligation to update this information.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><br><div><div style="line-height:150%;text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">2</font></div><div style="line-height:150%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a03242014arctenderimage1a01.gif
<TEXT>
begin 644 a03242014arctenderimage1a01.gif
M1TE&.#EAP@&.`/<``(B\XL/'%=+53\7&Q.(`,>0//>8?2N<O5^D_9.M/<>U?
M?O!_F.]OB_*/I?2?L?:OOOB_R_K/V/O?Y>'CBO#Q\/WO\O___P``````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"P`````P@&.`$<(_P`!"!Q(L*#!@P@3*@1@H:%#
M"P("2)Q(L:+%BQ@S:ISPL"&%`2!#BAQ)LJ3)DRA3JES)LJ5+EAT;(B!`LZ;-
MFSASZMS)LZ?/GT"#"OVY(*;1A@N3*EUJT&A$C5"C2L7(L>/'EUBS:MW*M>M)
MHS.'BAU+MJS9LSJ+'HW)M*U;A$ZGRIV[,>95KWCSZMV+%2S:OX`#"QZK=NW#
MMX@1QZ7+N''5AW?Y2IY,&:_?P9@S:P9<V##2Q*"7+FY,>NICAY$KJU[-VN3E
MS;!CR][9V;/MV[ASZ][-N[?OW\"#"Q].O+CQX\B3*U_.O+GSY]"C2Y].O;KU
MZ]BS:]_.O;OW[]L;5/\`3_YW!`CHTTLHS[Z]4?0+XCN`L/YHA07U;4-P$+\!
MA/$QH7>4`PD40(`!"D!PU`([W48;<!#D5-MN#.J$FP,T*;A6A`1`D,!.&MIF
M``$)6`"B9PKH%**(.1W@684]31C33#)V%!9.-<Y(``)&T13!6C#B9-@!!,C(
M84XK'G7C34G>UD!-23YI$P.X2<FC0Q$0\".#"#!HP'@-%-!1D#<YF%9O(QK0
M$)$Y%0"@;F3:U)$$!A+0&X<A'HE3B0'2Y,!#)_88J&YZXO3F0Q5V%$&=.GUI
M8Y&V+6E3;586%V=-OA5J4Y,-I7AF<A_^9,"?QUU*DYD2YB;E`P,^B)NI=C[_
M&NMN>+Z&DP0,$."FH$@>Q2A.K-+*TX*GHMB3@3DZ)&E-M4E`TY7#P9KIH!V-
M^*ET#EC;$ZF]26N;JVM58""TMVE[TZZ&>8M;6)Q:4.M:#^"D@&?4&F5JNS&)
MFQ.5Z1:KVZ(X1GJM;73Z^VJ#=]8;DZ<X%9"?;AA.6).CN#%,4P/N9:RQ<N=!
M$-\#`G8WW\8:5X`>?_[11^&/1IG\P`(IDRSSS#37;//-P>5*@(L=O8FAKFM9
MB_%#%=04;$.'TDO3A##&].Q:YR5ME`0J>X;>>!7BZQ"#1_([YXY'<MHQO@]K
M/;;56F/Y7[@//>R0!%(3777+;T:0=`5L)KLF36)Z_^8`N0Z9S#+;6$Z]%MP.
M03!X3&/';0'B#2T.'9M>&^4IGS$YZV-'\=)TJ`1N*PUI3&S.VM#3,BUM%)OH
MH3ZFZC3QC&B&MC$X>X8SY1<VT2D>4-],Y&;]$+N!?X@`@*Z[:V`!P3(X;T,<
M#MUOAP^]"[WJ%LPD.Y#8-R2\]]T?E25-S]_&8=^O[^A0\MD;;,'W[]-.M.NY
M'L!R6+=W!C_2=:Y70/DX"Z``@;,H`#[D26D;8,;V)QUG&5`WH8G@0D93F@IF
MY#0>:8T&-\@:6\WF@R#,C-X.(\$2-B4F3[&@"BV"00NDAH,PC"%7/!C"&MJP
M+"-TB`EW.!`*KO"'+7RA#/^'2$25T/"&2$QBC'+#0Q[Z\(<J#&(1ITC%K^A(
MB5C,8JIPT\0=/A&*%91B%<<XQB-J\8PWS*$"U\C&-KKQC7",HQSG2,<ZVO&.
M>,RC=RI@+B9YIG,Y45-P8`0XWO`18?EZ@,7D=Q2=@0LWFKI)(>VS2%VUJP++
M\IUM\-:3HWG&D=)[SR/;UH#2L>]T-E&`)^-G(:(YX%<R<N2>="-+FR1`<@YY
MP+*HUZ>::-(H8;I)9\3U)RY9@$@84P#FP-=*T06L-YI3V,&:.;O,(0"7U:.=
MOMKT25TA3T5!TPGZ<A.JACDN41;XV4XFF;H1[G)TU2JD`RJ7&W4)"YQ'B:2?
M@(/_0%GAA`&.>X@!)AG,`R0@39R"E5G4Z!!//2R:.&$G]X:2,%YN;2?<LL"(
M'BA-?3)2-SP)Y45-1S13-NQ^\%S+.]=I*43>LU>]Q.=R'O"KGV34-_9<RRCS
M&3L$^/2G0/5I'S=UFYPV!$-K2<#VLFG1GO%DE8"2Z14;QIMW"M)>[C.,.K=H
MF'?*R*?V26GM7$HH::9.)S<=CN=PP\F<^.:04@7F3I9Z0)N$KIMFA6L@XR:!
MOT4TK#7!YD,\A:ZU2"DGRS1,!2K)//$-]7BW&=_.?E,ZO4DV)P^$'@.&FE;%
M#K4F(L5-.6=YFPK4LB8%6(#C=.G+NYH()P;`5Y`.$%`]_]KVMKC-;4,ZIX"4
M$38].CO:C3(+2,"I,T'I@4`I272XFI0/`HZD*X<DNIS%?O0HI:-N.FW26=U:
M!Y-\R^A]:I)8[_XF5.6]W4]6>5EAYH8GL3U*\D9$5VNIQ:$=\=25-+=*!F+U
MJ#7AEKCZMCN'I$F@ZFOHQ1[2/X>,*ZKD>K!#=,8M#!D0M`X)549U%LJ?J45?
MA_*4["H$0.(Q4V_E3.!#?I:DGUU5<Q1#)0$>AC\%I[1@!"#53,:YX]M5CG4(
M)H`GG^3:V^`X66Q*KP4.Z[:F8;6P.J4)/250NL45#6@.J=3L*%8PAS%50]$L
MWS854-OV)4G#G(.20]2YG@J4L_\"<+9`J#QIX@KM2@)A<5%]4I2`N<7T`,&"
MP$P&%ZH552B4'/*:M5(['@DPR&L5TM\^=TN3!(S'`0%M:XY;EB)2;7-%FI.>
MY@`7EA`SLD*5XU"P`*D@T]8$SN/1F:2%/+6:%-F\N&X.CF\RJEQCIP*O?)9@
MD1.D[C*QBR7\(AA)(T8R.IN(9D2CM#_(4&0G&X7+!J)=GLUM&49[VN#>3+6M
M'4%E9YLNS>ZVNCLXU7"[.S;C)C=HS'UNN:1[W?B>S+??S6^TQ%O>BL%VO<.X
M[7P;7#+[[K?""7-L@`>\(RD<N&,*?O"*6Z;="\_X0AON<+?06^)0N;?%1]X7
MC&O\Y$/_^7?'F?)QD%^0XB2/N4L2CO*:/_,V*W]+RUU^$9'+_.=6]*?-A[Y$
M7QO]Z$A/NM*7SO2F._WI4(^ZU*=.]:I;_>I8S[K6M\[UKGO]ZU*/#P)JJA,$
M*``_CUN``DS:J"X9VUA7W0U_QBZ8)'GLH#[)K&T.NY.!+N#M2%O`9WU*=D;;
M1JD^4?+;%$#WG"#@3XYFP$K',DG8J.7NGX5M`A:@XG1.7E[!.B2^(O!Y73%@
M/1&J#2=3IC(+Q\2HO+JY;[9*`+W7DZQ'89C6.)3Y3>-&<Z=EUB;93FO/;-,F
M!1CV2.=:YH9(N*L#$U^=*C_IU^,>:?8595SM0WS:X@9@:LYO_RHWJ2UR-4"0
M7@+>>IR5/K=^*_K_PNAO8!^AA36UEPKJ_:U3)TBS-B3SH648$(5\158AQ]<F
MRD<C`L-5B%)(!5!YR0)[@2-6U[-];;,3^[<AU[4L@)=E"99+._)3#*!+"'``
M7J9>0O)^#)@;^F)V&-@MN'=E%05F<[46/S,X9@4K#+5F.Z%DZ'16\J<C[@1_
M3Z)=<')]YI-7-4AL/=%KRZ&#\1&%4AB%.R4PA45V-!%WT^1^T/4K,[AB.T%/
M5U8;'<43G=<19HA5),5,83@\%&ARJE,!BF031GA[U%16%OA:>3@<@`04ED8<
M$HB&\&<8.H-+'F5[:NA^#<%W7RA^^/_T(5HH8SC!*1YU?[B1AM:WA@_17G^E
M@)[A5<53$W6XA2G(&Q[%*5>F$U"E'`_0>S"%4T@HB"MH@\\RA5-(?-7W(M<W
M(HT8$ZXX8_*5AWQW$_3D)&VHAJ7UBT,XBUDRBD45BU9C5L.(?,E!``'8,PN`
MA7PS?]"X/H/X-;6W+B^HBW>(-.W"(#5B/8SSC9+H1RJE$]=X%'UH$Y%X.[LQ
M6I.R@++W-H(U(F?(2HKX4I-H&+W7?(:!2[$3?Z7(&X$85;-X@6O%@CL!99D8
MD(9A,1IHB1W!=W3E-.P8.,37@9RX,\UG@+TQC,OX5P13.HI'+.4(2?X'DCJ!
MB#U#6`@Y?IO_]"OQJ"2$]Q,'X%,_0GHE^!,/B`!4,GE@Q9.EEX54(GF-%QB=
MX5=M5XRI<U=_@P"_R#<^194]<WY"87B?^)0W\9-<"37A$SD^A8MFT7Q.J8UC
M"90V*%2BXE,=Z'E#H0#[%SOSL0!L)Y8'4I=@%YB".9B$69B&.3/\88OQ<350
MPP`_61T1L%GQZ#%2N).Y-(6`>9@O`U0+$"P-D)E'9P##%&`/X9@/D3>M@F6W
M4X_9HS7"YXAT=4K/X5\5&8X\I2W_*'5TDD.A0I%UY8Q,%TW*5R?=)261J%_9
ME($R5AOJ!%7L@R&I!3<5XGU88B`)DD[+LTI\-AX1D&)C90&`U"P'_^(NX=<0
M!:,AG:,A09*-!U(3E3,^+",E#\-)!O`CBZ06$F``H[(?Q.D]C`(!XU(G#``P
M!V`M6I@BG"=HY%.!%T,DC'(E]Q$67<)Y1W%8H&D!G(0`K`(!;,(MV94K!E`Z
MCJ8K-Z(66^4IYG(T^A(LX^.9-A%,VE(^.%9>NJ*<&0F,@%5\,:$SA106`/1*
M('665,8WDN,ZD;:.GC-=1F$M?T)?F9A`ML.&I&(`Z%)@F<,`TW<[*V)BBJ(`
M66I@JHFAV'-E/QE46SE2*Y*>3*46D&BF/S52LQ8B1SH]&@E8'1DJA<$^-8:F
M?,I4A>1HVI(_6EHM\I,E%QH3/S-.F1-81_\1*@^$FA7:D;(H(VRBJ*[C8H*B
M)JF(2Y[R(_TYJ+KHB!]EI1S2&<`#JF>E(3^34>R#-YL',Z%C:_E2G\RT(NI8
MJIUREM[S/'-:JW!J&^I4EKY($U!5(4>CI^X#/PST,ZPR/I6SIZP4IXL:.ZRY
M+C65E*?):UX3`7WY)\&WAQ:P63V!`.+1-B:%`/G!GJ*9(K3:$1`P(O^S6060
M5L'&-PS`(`?0`*Z5+9(T/*'DEP7`+ZT8.T5!4W]IL*+85[]R)5ZY,W\2;/$%
MGFX)0+44L>]C+NB*L'SS`$,Z,9?71]MJ+H`VL*V5JY5FD/R*6:%#>KIR=B-2
M&!)0(!XK9V/I:+__HDFHQB@%(%+OFH5%`:"ZX@`D&SL1H+$[$SH,<JB'>4<<
MTI%X0Y.'29O*(0$-T``1T(S`D7,>)W`\-Q<^!W1@*Q(T1W0VIW):.T%<V[6F
M`7-AV[8A,;9DBW)F>[8)L7-J.Q%?Z[9`![=QJW%S2[<'8;=W&P!YJ[<RQ[=]
MNW!_"[@%(;AW6[B&2W*(F[C]MKB,VT-I.[AU8161J[>32[GO9KF7RQ"9J[E4
MP;:=^W.?"[KA)KJ7Z[AJ"[FI>W"KR[K3YKJ,"[M=*[NSFV^U:[MHA+N`J[L\
MQ[N]NVZ_"[Q:)+QT2[PN9[S'VVW)J[Q8Q+QGZ[P@![W1^VS32[U)9+U:_XN]
M$J>]VTM&W>N]:<1QHWM"$&>Z44&^Y5M%YXN^-02^.2>^`P>_\3M%\TN_(&2_
M*X>_]::_^PMM<.B__`;`'2?`YT;`!>QM!XS`[J;`#L?`V>;`#PQ#_2O!\*:^
MZTL0%KQL&)S!&[3!'"QN2YO"*KS"+-S"+OS",!S#,CS#-%S#-GS#.)S#.KS#
M/-S#/OS#0!S$0CS$1%S$1GS$2)S$2KS$3-S$RN&F4!Q401G%5"RL`FB-ON&4
M5+S%4"PY5\G%U]0;F`3&1ID;#^"8/'$`JI0;8/R'!\G%?R*49#S'5#G'=OQ3
MI/+%=@R:CJ:6!9``F+:1=9I+^.A+Y>H0!S`AF/_TQ_ZQ`#,AAI6$?,,&?C,9
M'*FHM(/%$V;JBOA">SEAD(3*$U";2V1WG6_#GLB70QU;A?E")M>8GWUGIFY)
M?;#U4[T'5)\U(9Y\$Z#)H3IQ``PP'QZC`.;R@.7).3J+=N;9L.Y5FLQ#)`;P
M(2Z"(:OTK9KHD0^Y&[^B?,_XDN9*5#<J3KN1(FZ90YJ&6MR\+,E',&ZI*]QL
MGEEH&]JH-_7Z@0[I>^VWD#*IJ^0)KB75)@DTC4VR:R?H6/F8.,!H3"-")4B%
M@F6B@OO(&T-EHRYID?9A+;OG)TO8S0,(SN%"?*.XRP5=T3UX&X^LC\T<C?;L
MC1(5B+@:4P-I?,3GFP?_^9_@B&&V`7[D0E/@8X*^ER7Y_-#.E-*]L4N*2B'=
MR&"#W,^M4\G`2CLQ.8^^=(39S$QJ2:R?^(9"=]"V$2^5)ZELJ,\=$3':]XHD
MC9-5M8&\EALC`C@&0"6]HU$$0"5J'-1R`M%$/<Y]QXTO&2\Q$2\933V[S,\0
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M-O$RXIK@XWW3L`6"EEB&,1EE%FCA;=/.CO+CGXU9#;``,BN*]DWD^&WC"!WF
MP^%F0_'?8>W:8C[@+?-\6VU7=FB1A\7@['T3):(YG?]E5D<ND3N!360^UCTA
M>5KMABLHH6\>X$4^X>THV<R1LB8.'`WIC54]K-4JUVT"RD;%(83.X?MBG3DN
MYQD6Y3SURRYY&U=-V)0>T2DBY'2*Z7'NCC%1R&Z.'&NC5;\XV[3MZZ+.YW\^
M%*5NY9BRH]<,GNRDCM`^[+$'[%S>KTR>$X+UZ$9!R:,.A)S^@&MQKU0-YX9Q
MBD?1W[)Z',QE9"O%U^J^Z1MN&*&2@;U=A_1WS453[==%Y5V^Y]KNKHV^&T&X
MX]T\[NWSD([<*J`9ZN%<\/J-6,B1BS)=[\FNYZ_.Z8YHHX@-M1)?YEBL?5JS
M2[45D_H$UI8#KN#^T0P/BJK_\MP+K^P3[]&=[?%.(C%8K=AT2.\VO]TZSTR@
M.8WWGHA!;[):,NMITT=I0^>[-(J7\MBU;HK,3NYHG?')O?%:CH>:_L^.QY"Z
MFO7&@EJ@W/(O+J8?64Z\4=[":LUIX\L3LQ:>HC?'!W@>9<YLM\[A,E14GU0]
MW_;'W?&.#:RPU.V&TAM2?<PPCUC-U[/NG.VU5V:RQ.N!,WD%@"^5./D]4TL'
M<(8'V#!-8N?C"E17395&:P"W!GQ^TQ.CO%N/%<@8.H?G,N*[M;`4331UDBSB
MWB9!Q<FZ4=X8_]2BG!N0WR+W&A^2/O@U+DD.D!]RN"1N3"&*6?U2N'[6G_W%
ME/WQ_P$DW&^+#_O]XJ^89?/]W14!W469XQ^%F1F95XT@2_YZYL\;9#TGZW__
MW0^L^!\?1:;^]W^&`"&A08("!`P>/%@@08,*%AP^A/B0@(&&#R,P,(`080('
M$3U^!!E2Y$B2)4V>1)E2Y4J6+5V^A!E3YDR:-6W>Q)E3YTZ>/7W^!!I4Z%"B
M18T>19I4Z5*F39T^A1I5ZE2J5756M)I5ZU:N/BMH!*N1@06,&@N,=1@!0<&$
M8QT@"`O6P$<'9>,2.-`1H@.V!!`$Y7L00D@("^`*)IG18`$%>KL^#ME`<0$$
M"`X<O+P`,E(%!!Q;.*P`XF6L#`Q2_"CAX&<+$`Y*\/BU@?_(@YHANC9H&Z+!
MOT(7&!P\\O=KD8J!;Z;Z@#7("I?Q8KW-&WG1"G,A/C@(?8%NU08C@.Q,((%'
MYV@]CJ>=V^-P`AZE^SXN7#SQCW`;()[^M#D!W2&Q&UPN(@-ZRP\IQ?H[SR#T
M/(J`OH<<R`ZBQDRJS:/P#G#/+P830,B`!:!SJ`(%^F(,MO4*RN@`#@D(3J3?
M0%L,1`LZ@P`W%B-Z($6X"OA,H,L@D&!$`A@#T8$4+RO@@=C",^B`QFHTT0(1
M^T+@N[TXE#(!Q1!HJ((&G#/`RKV,\Q`B"1S@$((*[$J@HOTT0M"B@T0;J0(Q
MI5S`./'NM$""/,=[X#`>'8)``<7_S)/R+18A(.@T)2&*0,<A^_.111$5:S,M
MC<),R[B7[AM2I`8-4F`[4TT]U"/%%*BQ`08*P)!"4FLL3-``WR,T/H=`/<#-
MC!`=E0`Q38OU(>=:#.E%"R:+Z+>.;$2VLP)V(X#./HUCR`((0WT(+@(M4.^A
MX;!2S`$@';HLRO\*:$B"2`^:34JVSC+QL$<MN"]>A\H-<<5J87N`K2B'B[-9
M_$ZZ[-L*V'HT`O8.,!'4`I+4=**'WO2L(0B<8]<AT]I[*","*SB,OX:V!=FA
M;:U[2#5$66(KP&X->OFA_P@`4>(0(<B(S_2JI76@@ZK,D,#_X@35NH**;?F@
M[\);3]=D_U-6C&4(;8/VM@2031BBX9`]K,4'6*7V6UQ;"W=9\4[-DU1QI?XZ
M.OYVG8CMDM^>&^\6"1[)7V03,RBV@^X]&\:4'0IO8*G)<MN""!2XUP+GO$Y[
M1JFW_=8`IEGZ>',<#PKIP`P]V\O:DBJ,*-@%'<+5WH\$P^W;AU;4K'`+XI;O
M8K;^@M#:K"-BE``&)/"6\AMG/OXA"-9:H+MOPVL1-RMQ^_LCW'--'NV\BY<O
M;X>NYULD4$DW*7;K%91(0X@.,SCYZQURWLS.%"`^<+S[>_]V]"V7,:6O%A>0
M0?05D6U-*R*=$Q5)4!>1NY4-;Z8SED$J@!L#MF\V$3)>]:)FIO^#9&1UOW,(
MAU#C$.Y]3VIABR#3"A<!YU1&>');'4C>1SVYV>8P49)AY<!7.9!,IG^IP:#Q
M=%,X]F50;\"C&>*&A)4BFM![^LN>$QM#@,BQ)#PQC$C20A*SB'0GB@\BW\_B
MY,48XFIAB^N.;594LQ0I$2_MJ^+YH./%S8%P.-8Z(]/>AT+&5:MIZ@O1`6H6
MD17U*B(*(-`,I88;V]R,3Q`R4?B<N#<>@J1D,E,9`6`S'-E9@$,5!!<@26B_
M(TZ2D!;#EQD5(T0C6N@@@TQ)R2"X%\RDIB_(.J,`OS/!!]AEEAZYF0$>T"HF
M4>PZ3I-0XQPWL3MMRY!2R@PM3[,`:2'_!).XR93R4`D1?R&J+R([C`$*\!VV
MX%$Q\?I?D\0#)@/J"2$(&""3-.*8=`YP1=_28L7`8KK#,.TP"PK6`2SSPQ"5
M#`$.@,T$7U4`9$6@(..<G1\?,CX.&B1RY\0;`1H`&P@4!%'&N8R*3@-1YZRN
M/"#A4"<+!)0*.,!4&K29J1Q`4`@TP$H1\!E/(H!#.[7D7!>[DT,;\(!3,>`P
M<W3I`F`:D\(LX`$$+=]&4Q*!!ISJJ:*2*519\K4)FNN'.`4>3`BBU966U:QG
MC&.(<&;6KN3O)[_)*5OE:M:2FJM&8Z,,6>?:%-?Y1)["VFM@Y^JE!%0&`0N(
3JV"A8E3#&K8G!VNJ3%I3$A``.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
